Quick Answer
BeOne Medicines Ltd. reported Total Assets of $8.19 billion for the year ending 2025.
- BeOne Medicines Ltd. showed an increase of +38.3% in Total Assets from 2024 to 2025.
- This data is from BeOne Medicines Ltd.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $265.23 million | Q2 2016: $251.23 million | Q3 2016: $235.43 million | Q1 2017: $376.73 million | Q2 2017: $473.98 million | Q3 2017: $1.05 billion | Q1 2018: $1.71 billion | Q2 2018: $1.65 billion | Q3 2018: $2.41 billion | Q1 2019: $2.17 billion | Q2 2019: $2.15 billion | Q3 2019: $1.88 billion | Q1 2020: $4.07 billion | Q2 2020: $3.90 billion | Q3 2020: $5.57 billion | Q1 2021: $5.82 billion | Q2 2021: $5.52 billion | Q3 2021: $5.29 billion | Q1 2022: $8.02 billion | Q2 2022: $7.38 billion | Q3 2022: $6.73 billion | Q1 2023: $5.96 billion | Q2 2023: $5.73 billion | Q3 2023: $5.52 billion | Q1 2024: $5.67 billion | Q2 2024: $5.71 billion | Q3 2024: $5.83 billion | Q1 2025: $5.84 billion | Q2 2025: $6.30 billion | Q3 2025: $7.63 billion.
- Over the full 11 years of available data (2015 to 2025), BeOne Medicines Ltd.'s Total Assets has grown by 6,912.9%.
- Historical annual values: Fiscal year 2025: $8.19 billion | Fiscal year 2024: $5.92 billion | Fiscal year 2023: $5.81 billion | Fiscal year 2022: $6.38 billion | Fiscal year 2021: $8.54 billion | Fiscal year 2020: $5.60 billion | Fiscal year 2019: $1.61 billion | Fiscal year 2018: $2.25 billion | Fiscal year 2017: $1.05 billion | Fiscal year 2016: $405.81 million | Fiscal year 2015: $116.76 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: